Navigation Links
Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
Date:5/20/2010

"xn-person">Andrew R. Haas, M.D., Ph.D., Hospital of the University of Pennsylvania, and investigator on JX-594 Phase 1 trial.

This open-label, dose-escalation study was completed at four sites in the United States and Canada.  A total of 23 patients with solid tumors refractory to standard therapy were enrolled.  Patients received a single treatment at one of five dose levels, with follow-up at periodic intervals.  Six out of eight patients in the higher-dose cohorts evaluable to date (cohorts 3, 4, 5) exhibited disease control as defined by stable disease by RECIST (Response Evaluation Criteria in Solid Tumors) criteria and/or Choi (necrotic) response.  Two out of six patients in the low dose cohorts exhibited disease control (RECIST stable disease) but no responses.  The primary endpoints of the trial included safety and determination of the maximum tolerated dose given through intravenous administration.  No serious adverse events related to JX-594 therapy were reported and no dose-limiting toxicities were reported.  A biomarker analysis further strengthened the finding of dose-dependent replication in tumors following IV administration.

About JX-594

JX-594, currently in Phase 2 clinical trials for liver cancer, is a cancer biotherapeutic product from a proprietary breakthrough class of targeted and armed oncolytic and immunotherapeutic poxviruses.  Tumor destruction and safety was shown in patients with diverse cancer types in three Phase 1 trials; treated patients were end-stage and had no effective therapies available.  JX-594 multiplies selectively within cancer cells, leading to their destruction.  These newly created copies of JX-594 are then released and are able to infect and eradicate other tumor cells
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
2. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
3. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
4. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
5. Jennerex Closes $5 Million First Tranche of Series C Financing
6. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
7. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Bioptigen announced today the availability of ... optical device metrology and pre-clinical ophthalmic research markets. ... Contact Lens Metrology is designed for non-destructive, non-contact, full ... IOL structures, and donor tissues. The metrology ... in a hydration bath (saline), automated segmentation of anterior ...
(Date:9/15/2014)... AUSTIN, Texas , Sept. 15, 2014 The ... changes in climate, says a new article published by the ... Ahmed , PhD, on climate change and its effects on ... part of an extensive study conducted by Dr. Ahmed in ... China and has implications for the future ...
(Date:9/15/2014)... Maryland , 15 de septiembre de 2014 ... se llevará a cabo del 12 al 18 de octubre. ... (PPTA) y de sus compañías miembro s, la ... la concienciación mundial en torno a la colección de fuentes ... donantes de plasma al salvar y mejorar las vidas ...
(Date:9/14/2014)... variety of ways, including by modifying the protein structure. ... form and perform no or even the "wrong" function: ... diseases such as Alzheimer,s, Parkinson,s or cystic fibrosis. Some ... other molecules of the same type and congregate into ... damage cells and tissues and make people ill. , ...
Breaking Biology Technology:Bioptigen Introduces Deep Imaging OCT System for Contact Lens Metrology 2Tea Taste and Quality Affected by Climate Change 2Tea Taste and Quality Affected by Climate Change 3Tea Taste and Quality Affected by Climate Change 4La International Plasma Awareness Week será una celebración para los donantes 2La International Plasma Awareness Week será una celebración para los donantes 3Measuring modified protein structures 2Measuring modified protein structures 3
... material that could become essential to efficient, environmentally ... advantage of graphene,s outstanding strength, light weight and ... wells. The Rice University lab of chemist ... Texas-based supplier of drilling fluids and subsidiary of ...
...  Kensey Nash Corporation (Nasdaq: KNSY ) today ... (Nasdaq: SPNC ) that they reached a ... product lines purchased from Kensey Nash in May 2008. ... payable to Kensey Nash.  As previously disclosed, the Company ...
... Sangui enters commercialization phase / Initial order of ... Tamaulipas has issued an initial order of Hemo2Spray, the Sangui ... product Scabremove both registered by the Mexican authorities in September ... the wound spray and Sangui management is positive that an ...
Cached Biology Technology:Functionalized graphene oxide plays part in next-generation oil-well drilling fluids 2Functionalized graphene oxide plays part in next-generation oil-well drilling fluids 3Mexican State of Tamaulipas Starts Training Doctors in Sangui Wound Management 2
(Date:9/16/2014)... years after the Hesperides vessel returned to Spain culminating ... have an increasingly clear picture of how the global ... the input of pollutants from the atmosphere is not ... most remote areas of the planet, and it is ... are presented this week in CSIC Residence for Researchers ...
(Date:9/16/2014)... . CRG researchers ... Journal of Cell Biology describes how Topo 2 ... , At this very moment thousands of our body,s cells ... the body repairs damaged tissues and regenerates others like skin ... "mitosis", during which the cell duplicates its genetic material and ...
(Date:9/16/2014)... Sept. 16, 2014  Cross Match Technologies, a ... announced today the launch of its Verifier ® ... identity of an individual using their secure credentials ... rapidly reads credential documents with embedded biometric data ... the biometric to a live scan of their ...
Breaking Biology News(10 mins):The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 2The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 3Unraveling cell division 2Unraveling cell division 3Cross Match Launches New Identity Management Handheld Solution 2
... ROCKVILLE, Md. -- Several members of the American Society ... or foreign associates of the U.S. National Academy of ... in original research. Three current ASPB members were ... Birchler , Curators Professor of Biological Sciences, University of ...
... Callaghan, a researcher at the Royal Swedish Academy of Sciences, ... and permafrost. "The changes we see are dramatic. ... deviate from the norm when compared with a longer term ... parts of the globe that is warming up fastest today. ...
... and Shinya Yamanaka, MD, PhD, have been elected as members ... in original scientific research. It is one of the highest ... States. They join 70 other scientists who will ... now has 40 current faculty members in the distinguished group. ...
Cached Biology News:A new research report shows effects of climate change in the Arctic are more extensive than expected 2A new research report shows effects of climate change in the Arctic are more extensive than expected 3UCSF scientists honored by National Academy of Sciences 2